Fixed combinations in POAG and OHT patients


An overview of trials comparing topical medical therapies

Intraocular pressure (IOP) is currently the only modifiable risk factor for the progression of the disease, but there is no ideal IOP for all patients. The risk profile of each single patient should be carefully evaluated before deciding treatment algorithm.8 The initial treatment of glaucoma is typically to prescribe a single ocular hypotensive medication to reduce the IOP. However, over time, the pressure may again become elevated requiring the addition of a second medication. Approximately 40% of subjects with ocular hypertension require two or more topical medications to control IOP.9,10 When target IOP is not achieved with a single agent, combined therapy using drugs with different mechanisms of action is recommended.8

Multiple local therapies may be associated with more local and systemic side effects11 because of increased exposure to preservatives, with a higher incidence of ocular signs and symptoms and poor compliance.12–14 Fixed combinations (FCs) of two anti-glaucoma drugs have been formulated to obtain a greater reduction in IOP than that which can be achieved using single agents, to allow fewer doses, and to ensure less exposure to preservatives.11

Related Videos
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
Related Content
© 2023 MJH Life Sciences

All rights reserved.